Remove Gene Remove Genetic Analysis Remove Medicine Remove Protein
article thumbnail

Unlocking the potential of mRNA for the future treatment of rare diseases 

Drug Discovery World

Now, given the extraordinary success of the Covid-19 vaccines, the mRNA platform may bring renewed hope as researchers explore its potential to advance medicines for rare diseases. Interestingly, at least 80% of all rare diseases originate from monogenic mutations, meaning that they arise from mutations in a single gene 4.

article thumbnail

AI test could predict best cancer therapies for patients

pharmaphorum

The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs. The post AI test could predict best cancer therapies for patients appeared first on.

Protein 67
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from SLAS Europe 2023

Drug Discovery World

Managing all of these elements using iterative design and prototyping can play a key role in successful project delivery, and marrying technologies with biochemical or cellular assays has the potential to bring disruptive change across fields as diverse as personalised medicine, diagnostics and drug screening.

Doctors 52
article thumbnail

Blood Donor Day 2023: Experts weigh in 

Drug Discovery World

BCA members also operate the BCA Advanced Therapies Network which is a diverse, fully integrated portfolio of blood, cell, gene and tissue materials that support the development and delivery of advanced therapies. One example we are following with anticipation are the two FDA approvals for the first gene therapies for sickle cell disease.